BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 29
• 30
• 31

• BioMidwest

  Medtronic, Inc. CFO Gary Ellis To Speak At Oppenheimer Healthcare Conference

  December 8, 2014

   · 

  1 min read
• Rhinomed (ASX:RNO) Mute On Sale At www.mutesnoring.com

  December 8, 2014

   · 

  2 min read
• Genetown

  Cheetah Medical Inc. Release: KOL Tells Attendees At 4th International Fluid Academy Scientific Meeting That Current SOC Guidelines For IV Fluid Management “Are Likely To Lead To Salt Water Drowning Of These Patients”

  December 8, 2014

   · 

  3 min read
• BioMidwest

  Case Western Reserve University To Lead $27.3 Million Federal Grant For Sudden Unexpected Death In Epilepsy (SUDEP)

  December 8, 2014

   · 

  9 min read
• Business

  Aethon, Inc. And Becton, Dickinson and Company Announce Collaboration To Develop Integrated Medication Management Solution

  December 8, 2014

   · 

  3 min read
• Drug Development

  Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology

  December 8, 2014

   · 

  3 min read
• Drug Development

  ERYtech Pharma Reports Additional Positive Phase 3 Results From Clinical Study With ERY-ASP/GRASPA® In Acute Lymphoblastic Leukemia

  December 8, 2014

   · 

  10 min read
• Business

  NeuroVive Pharmaceutical AB Employs a Clinical Trial Manager

  December 8, 2014

   · 

  1 min read
• Drug Development

  Celgene Release: New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented at the 56th American Society of Hematology Annual Meeting and Exposition

  December 8, 2014

   · 

  8 min read
• Drug Development

  Celgene Release: Age, Renal Impairment and Depth of Response Analyses of the First™ (MM-020/IFM 07-01) Study of Continuous REVLIMID® (Lenalidomide) Plus Low-Dose Dexamethasone In Newly-Diagnosed Multiple Myeloma Presented at American Society of Hematology

  December 8, 2014

   · 

  21 min read